Profil
Denis G.
Kay is the founder of Alpha Cognition, Inc., founded in 2000, serving as Chief Scientific Officer.
Dr. Kay is the founder of Neurodyn Life Sciences, Inc., founded in 2006, serving as Chief Scientific Officer.
Former job includes Director & Chief Scientific Officer at Neurodyn, Inc. Education includes a doctorate from McGill University and undergraduate and graduate degrees from Dalhousie University.
Aktiva positioner av Denis Kay
| Företag | Position | Start |
|---|---|---|
| ALPHA COGNITION INC. | Grundare | 2000-01-01 |
Neurodyn Life Sciences, Inc.
Neurodyn Life Sciences, Inc. BiotechnologyHealth Technology Engages in identifying, validating and developing of natural bioactives for the early treatment of neurological diseases | Grundare | 2006-08-01 |
Tidigare kända positioner av Denis Kay
| Företag | Position | Slut |
|---|---|---|
Neurodyn, Inc.
Neurodyn, Inc. Pharmaceuticals: MajorHealth Technology Provides neurological diseases detection | Teknisk/Vetenskaplig/F&U Direktör | - |
Denis Kays utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dalhousie University
Dalhousie University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Neurodyn, Inc.
Neurodyn, Inc. Pharmaceuticals: MajorHealth Technology Provides neurological diseases detection | Health Technology |
Neurodyn Life Sciences, Inc.
Neurodyn Life Sciences, Inc. BiotechnologyHealth Technology Engages in identifying, validating and developing of natural bioactives for the early treatment of neurological diseases | Health Technology |
Alpha Cognition, Inc.
Alpha Cognition, Inc. Financial ConglomeratesFinance Develops pharmaceutical products for treating neurodegenerative diseases | Finance |
















